Latest News

Innovative HIV medications available but inaccessible: payer barriers block Cabenuva and Apretude access.

Medication abandonment disproportionately affects Black patients; PrEP users 41% more likely to abandon.

FDA extends Cabenuva to 2-month injections but insurance barriers continue to restrict patient access.

31,000 Veterans with HIV face unique barriers including comorbidities and HCV rates 3x the general population.

Post-PHE planning for Medicaid redetermination: extended timelines and navigator support for safety net care.

Study of 109,283 patients links HIV status and viral hepatitis coinfection to significantly increased liver cancer rates.

UNAIDS report highlights HIV-HCV coinfection rates among people who inject drugs globally and in the US.

COVID-19 vaccination priority for people with HIV and chronic liver disease amid immunological risks.

Merck-Gilead partnership on long-acting injectables Islatravir and Lenacapavir for HIV treatment.

Arizona's restrictive Medicaid formulary limits single-tablet HIV regimens and HCV agents post-expansion.

FDA approves Cabenuva, first long-acting injectable HIV regimen offering monthly alternative to daily pills.